Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
-
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
-
Sol-Gel Announces Health Canada Approval of EPSOLAY®
-
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
-
Sol-Gel Reports First Quarter 2025 Results
-
Sol-Gel Announces Reverse Share Split
-
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
-
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
-
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
-
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments